Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation.

Publication Type:

Journal Article


American journal of kidney diseases : the official journal of the National Kidney Foundation, Volume 45, Issue 3, p.502-9 (2005)


Acute Kidney Injury, Adolescent, Adult, Aged, Busulfan, Cohort Studies, Comorbidity, Cyclophosphamide, Cyclosporine, Female, Graft vs Host Disease, Hematologic Neoplasms, hematopoietic stem cell transplantation, Humans, Immunosuppressive Agents, Incidence, Male, methotrexate, Methylprednisolone, Middle Aged, Mycophenolic Acid, Patient Selection, Postoperative Complications, RECURRENCE, Renal Dialysis, Retrospective Studies, Transplantation Conditioning, Transplantation, Homologous, Vidarabine, Whole-Body Irradiation


Acute renal failure (ARF) occurs with significant frequency after myeloablative and nonmyeloablative allogeneic hematopoietic cell transplantation (HCT). Myeloablative (conventional) HCT is the standard of care for cure of various malignant disorders. The newer modality of nonmyeloablative ("mini-allo") HCT is reserved for patients with advanced age and comorbidities who are ineligible for myeloablative HCT. The present study compares the incidence of ARF between patients undergoing concurrent myeloablative and nonmyeloablative HCT in the same period at the same institution.